Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNS561 (Ezurpimtrostat) in Moderate COVID-19
NCT04637828Phase 2Unknown
- Sponsor
- Genoscience Pharma
- Start
- Nov 2020
- Primary completion
- Jul 2021
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ezurpimtrostat in coronavirus disease 2019 (COVID-19), sponsored by Genoscience Pharma. Status: unknown.
02
Drugs
ezurpimtrostat
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04637828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637828.